Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Breast 1

Conditions

Triple Negative Breast Neoplasms 2Glioblastoma 2Endometrial Neoplasms 2Ovarian Neoplasms 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Meningioma 1Glioma 1Fallopian Tube Neoplasms 1Endometrial Cancer Recurrent 1Diffuse Intrinsic Pontine Glioma 1Breast Neoplasms, Male 1

Interventions

Paclitaxel 34Carboplatin 27pembrolizumab 20Bevacizumab 16Letrozole 13Megestrol Acetate 10Cisplatin 9lenvatinib 8olaparib 7dostarlimab 7Metformin 7durvalumab 6abemaciclib 6Radiotherapy 6Everolimus 6niraparib 5Specimen Handling 5Nivolumab 5Medroxyprogesterone Acetate 5Magnetic Resonance Spectroscopy 5Gemcitabine 5Fluorouracil 5Docetaxel 5Biopsy 5temsirolimus 4rucaparib 4Oxaliplatin 4Fulvestrant 4Doxorubicin 4sapanisertib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Endometrial Neoplasms × TIC10 compound × Clear all
NCT03099499 2024-12-24

Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer

Fox Chase Cancer Center

Phase 2 Terminated
19 enrolled
Gynecologic

Endometrial Neoplasms

NCT03394027 2022-08-23

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
30 enrolled 15 charts
BreastGynecologic

Neoplasm Metastasis, Endometrial Neoplasms, Breast Neoplasms, Male, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡